Last reviewed · How we verify
Rebamipide effervescent granules
Rebamipide effervescent granules is a Small molecule drug developed by Biolab Sanus Farmaceutica. It is currently in Phase 1 development.
At a glance
| Generic name | Rebamipide effervescent granules |
|---|---|
| Sponsor | Biolab Sanus Farmaceutica |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rebamipide effervescent granules CI brief — competitive landscape report
- Rebamipide effervescent granules updates RSS · CI watch RSS
- Biolab Sanus Farmaceutica portfolio CI
Frequently asked questions about Rebamipide effervescent granules
What is Rebamipide effervescent granules?
Rebamipide effervescent granules is a Small molecule drug developed by Biolab Sanus Farmaceutica.
Who makes Rebamipide effervescent granules?
Rebamipide effervescent granules is developed by Biolab Sanus Farmaceutica (see full Biolab Sanus Farmaceutica pipeline at /company/biolab-sanus-farmaceutica).
What development phase is Rebamipide effervescent granules in?
Rebamipide effervescent granules is in Phase 1.